These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32097671)

  • 41. Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor-Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
    Wan Y; An S; Zhou Y; Zhang J; Zhang Y; Gan T; Liu Q
    Cancer Control; 2020; 27(1):1073274820944290. PubMed ID: 32959668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Checkpoint Inhibitors-Related Cardiotoxicity.
    Konala VM; Adapa S; Aronow WS
    Am J Ther; 2020; 27(6):e591-e598. PubMed ID: 31008763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
    Eigentler TK; Hassel JC; Berking C; Aberle J; Bachmann O; Grünwald V; Kähler KC; Loquai C; Reinmuth N; Steins M; Zimmer L; Sendl A; Gutzmer R
    Cancer Treat Rev; 2016 Apr; 45():7-18. PubMed ID: 26922661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
    Abu-Sbeih H; Ali FS; Wang Y
    Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
    Yan C; Richmond A
    Mol Cancer; 2021 Nov; 20(1):146. PubMed ID: 34758832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.
    Liu X; Wang Z; Zhao C; Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Li Y; Wang M; Zhang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):810-818. PubMed ID: 32017399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
    Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
    Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
    Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
    South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
    Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.
    Jia XH; Geng LY; Jiang PP; Xu H; Nan KJ; Yao Y; Jiang LL; Sun H; Qin TJ; Guo H
    J Exp Clin Cancer Res; 2020 Dec; 39(1):284. PubMed ID: 33317597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
    Zhuang J; Du J; Guo X; Zhou J; Duan L; Qiu W; Si X; Zhang L; Li Y; Liu X; Wang H; Zhou D; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):799-804. PubMed ID: 32017466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal immune-related adverse events of immune checkpoint inhibitor.
    Hu R; Chen M; Xu Y; Wang M; Zheng K; Li X
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):305-311. PubMed ID: 32573099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C; Martin Romano P; Voisin AL; Danlos FX; Champiat S; Laghouati S; Kfoury M; Vincent H; Postel-Vinay S; Varga A; Vuagnat P; Ribrag V; Mezquita L; Besse B; Hollebecque A; Lambotte O; Michot JM; Soria JC; Massard C; Marabelle A
    Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management.
    Cheng Y; Ling F; Li J; Chen Y; Xu M; Li S; Zhu L
    Front Immunol; 2023; 14():1190850. PubMed ID: 37404814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.